Name: DC661 CAS 1872387-43-3: High-Quality Chemical Compound
Availability: InStock
Rating: 4.5 (89 reviews)

DC661 CAS NO.1872387-43-3

DC661 is a potent dimeric chloroquine derivative and a high-affinity inhibitor of palmitoyl-protein thioesterase 1 (PPT1), supplied as a premium research-grade chemical tool for investigating lysosomal function and autophagy-related pathways. This advanced small molecule is specifically designed for oncology and cell biology researchers requiring a highly effective agent to disrupt autophagic flux, offering significantly enhanced potency and specificity compared to traditional monomers like hydroxychloroquine (HCQ). It is ideally suited for pharmaceutical R&D scientists, academic laboratories, and biochemical assay developers who need a reliable reference standard to study lysosomal deacidification, protein depalmitoylation, and cellular self-digestion mechanisms in various cancer and degenerative disease models.

consult@huanqiukeji9.com

Send Email

Download

TECHNICAL SPECIFICATIONS

Item	Specification
Product Name	DC661
CAS NO.	1872387-43-3
Appearance	White to off-white solid powder
Molecular Formula	C31H39Cl2N5
Molecular Weight	552.58 g/mol
Purity (RP-HPLC)	≥98.0%
Solubility	Soluble in DMSO (>10 mg/mL), DMF; insoluble in water
Endotoxin	< 10 EU/mg
Biological Activity	Potent inhibitor of PPT1 and PPT2; disrupts lysosomal function, inhibits autophagic flux, and induces apoptosis.
Storage Conditions	Store at -20°C, protected from light and moisture. Keep container tightly sealed.
Stock Location	Stock in USA
MOQ	1g

1.MECHANISM OF ACTION

DC661 exerts its primary biological effects by selectively binding to and inhibiting the enzymatic activity of palmitoyl-protein thioesterase 1 (PPT1) within the acidic environment of the lysosome, thereby blocking the depalmitoylation of critical signaling proteins. Upon entering the cell, its weak base properties allow it to accumulate in lysosomes where it neutralizes the organelle's acidic pH, effectively disrupting the fusion of autophagosomes with lysosomes and halting the autophagic degradation process. This inhibition leads to the significant accumulation of autophagic vesicle markers (such as LC3B-II) and triggers lysosomal membrane permeabilization, ultimately interfering with the cell's ability to recycle nutrients and clear damaged organelles, which shifts the cellular fate towards apoptotic cell death.

2.PRODUCT INDICATIONS

This compound is indicated strictly for non-clinical, in vitro, and in vivo research applications focusing on cancer biology, particularly the study of autophagy dependence in malignant cells such as melanoma, pancreatic, and colorectal carcinoma lines. It is widely utilized by researchers to overcome resistance to targeted therapies (e.g., BRAF/MEK inhibitors) by suppressing the cytoprotective autophagic survival mechanisms that tumors often exploit under metabolic stress. Additionally, DC661 serves as a vital pharmacological probe for scientists exploring lysosomal storage disorders, protein homeostasis, and the role of PPT1 in tumor growth, making it an essential tool for preclinical drug discovery teams validating novel anti-lysosomal therapeutic strategies.

upload/attachment/image/202605/12/17785717285332c008ea25f53956c532226cdb1d77_local.png

3.CLINICAL EFFICACY OF PRODUCT

In rigorous preclinical evaluations, DC661 has demonstrated superior efficacy by inhibiting autophagic flux at concentrations 100 times lower than hydroxychloroquine (HCQ) and significantly outperforming other dimeric analogs like Lys05 in reducing cancer cell viability. Studies in BRAF-mutant melanoma cells show that DC661 more effectively suppresses long-term clonogenic growth and induces higher rates of apoptosis compared to standard HCQ or dual pathway inhibition, while in HT29 colorectal xenograft models, intraperitoneal administration (3 mg/kg) nearly completely suppressed tumor growth rates without causing significant weight loss or systemic toxicity. These findings confirm its robust ability to deacidify lysosomes, block autophagic clearance, and activate alternative immune pathways such as STING signaling, establishing it as a highly effective lead compound for anticancer research.

upload/attachment/image/202605/12/1778571748871bf8a4f0fd4c6c2bb3f4594bc56aff_local.png

4.Certificate

GlobalTech Co., Ltd. is committed to providing high-purity biotechnological peptide products, adhering strictly to quality standards and obtaining internationally recognized certifications.

Our production partners all employ GMP-compliant production systems and possess standardized quality control processes covering raw material procurement, synthesis, purification, testing, packaging, and storage. Each batch of product comes with complete documentation, including a Certificate of Analysis (COA), HPLC purity report, mass spectrometry (MS) chromatograms, and third-party testing reports available upon request.

We prioritize:

1.A rigorous quality management system

2.Batch traceability and stability data

3.Professional laboratory testing and validation

4.Compliance with international trade standards

Our commitment to quality, transparency, and regulatory compliance ensures the provision of reliable, stable, and research-grade peptide products to our global partners.

upload/attachment/image/202603/30/17748488791d02f82103a700e61eeafa024a96f6ff_local.jpg

5.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.

Professional and Secure Packaging

Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.

We can also customize packaging according to customer needs.

Shipping Methods

Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.

upload/attachment/image/202601/20/1768872924be74a0641f7ddbf20e541c97f2066c5c_local.jpg

Global Technology Co., Ltd. is a modern and advanced enterprise specializing in the production and export of active pharmaceutical ingredients (APIs), peptides, and plant extracts. The company invests in and collaborates closely with domestic manufacturers holding GMP, DMF, and FDA certifications, as well as laboratories at renowned universities, to meet diverse customer needs ranging from gram-level to ton-level. This enables Dejurui Pharmaceutical to provide customers with more flexible and convenient access to cost-effective, high-quality products and superior services.

We focus on the research and development and supply of high-quality chemical products, strictly adhering to international standards and quality systems. Our products are stable in performance and reliable in purity, widely used in industrial manufacturing, scientific research, and the fine chemical industry. We provide solid support at every stage with a professional and responsible attitude.

Hot Tags: DC661, PPT1 Inhibitor, Autophagy Inhibitor, Anti-lysosomal Agent, Dimeric Chloroquine, Lysosomal Deacidification, Cancer Research Tool, Palmitoyl-protein Thioesterase 1, Hydroxychloroquine Derivative, Apoptosis Inducer, LC3B-II Accumulation, Oncology Research

If you have any product requirements, please send an email to:consult@huanqiukeji9.com ;whatsapp: 34 686532411